Lunit Inc. (KOSDAQ:328130)

South Korea flag South Korea · Delayed Price · Currency is KRW
52,700
-2,900 (-5.22%)
Mar 28, 2025, 3:30 PM KST
-11.43%
Market Cap 1.53T
Revenue (ttm) 54.18B
Net Income (ttm) -82.42B
Shares Out 29.00M
EPS (ttm) -2,858.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 253,863
Average Volume 530,093
Open 55,900
Previous Close 55,600
Day's Range 52,300 - 56,000
52-Week Range 31,000 - 85,800
Beta 1.46
RSI 40.31
Earnings Date Mar 20, 2025

About Lunit

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such a... [Read more]

Industry Prepackaged Software
Founded 2013
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 328130
Full Company Profile

Financial Performance

In 2024, Lunit's revenue was 54.18 billion, an increase of 116.03% compared to the previous year's 25.08 billion. Losses were -82.43 billion, 124.0% more than in 2023.

Financial Statements

News

There is no news available yet.